Antidote competitors

Antidote Competitors include Durect, Amarin, BTG and Zogenix.

Add company...

Save Comparison Clear all	Antidote Antidote is accelerating the breakthroughs of new treatments by bridging the gap between medical research and the people who need them.	Durect DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases.	Amarin Amarin Corporation is a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease.	BTG BTG is an international specialist healthcare company.	Zogenix Specialty pharmaceutical developing CNS and pain therapies and featuring DosePro needle free delivery technology.
Founding Date	Founding Date 2009	Founding Date N/A	Founding Date 1991	Founding Date 1948	Founding Date 2006
Type	Type Private	Type Public	Type Public	Type Subsidiary	Type Public
Tags	Tags Healthcare clinics pharma	Tags Healthcare clinics pharma	Tags Healthcare clinics pharma	Tags Healthcare clinics pharma	Tags Healthcare clinics pharma
Locations	Locations London, GB HQ New York, US Carmel, US	Locations Cupertino, US HQ	Locations Dublin, IE HQ Bedminster Township, US	Locations London, GB HQ Rosedale, AU Ottawa, CA Düsseldorf, DE Hong Kong , HK Ataşehir, TR Surrey, GB see more	Locations Emeryville, US HQ Windsor And Maidenhead, GB
Employees	Employees 537% decrease	Employees 903% decrease	Employees 530120% increase	Employees N/A	Employees 68
Valuation ($)	Valuation ($) N/A	Valuation ($) 122.3 m	Valuation ($) 6.3 b	Valuation ($) N/A	Valuation ($) 2.2 b
Twitter followers	Twitter followers 1	Twitter followers N/A	Twitter followers N/A	Twitter followers 786	Twitter followers 475
Financial ⚠
Revenue (est.)	Revenue (est.) £2.2m (FY, 2017)	Revenue (est.) $18.6m (FY, 2018)	Revenue (est.) $229.2m (FY, 2018)	Revenue (est.) £620.5m (FY, 2018)	Revenue (est.) N/A
Cost of goods	Cost of goods £892.3k (FY, 2017)	Cost of goods N/A	Cost of goods $54.5m (FY, 2018)	Cost of goods £185.9m (FY, 2018)	Cost of goods N/A
Gross profit	Gross profit £1.3m (FY, 2017)	Gross profit N/A	Gross profit $174.7m (FY, 2018)	Gross profit £434.6m (FY, 2018)	Gross profit N/A
Net income	Net income (£4.6m) (FY, 2017)	Net income ($25.3m) (FY, 2018)	Net income ($116.4m) (FY, 2018)	Net income £12.7m (FY, 2018)	Net income ($123.9m) (FY, 2018)
Funding
Total funding raised	Total funding raised $ 17.9m	Total funding raised $ 20m	Total funding raised $ 70m	Total funding raised N/A	Total funding raised N/A